Abemaciclib, also known as LY2835219, is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth.
No Data
No Data
No Data
Qi, Yuxin; Liu, Yuesheng; Zhu, Chengchen; Zhang, Mingfeng; Wang, Tao. Preparation of abemaciclib intermediate and abemaciclib. Assignee Xinfa Pharmaceutical Co., Ltd. CN 110218189. 2019.
Jetti, Ramakoteswara Rao; Indukuri, Anjaneyaraju; Bommareddy, Aggi Ramireddy; Srinivasarao, Attanti Veera Venkata; Jebaraj, Rathinapandian; Chandupatla, Shivakumar; Batharaju, Ramesh; Kunamneni, Sunil. Crystalline polymorphs of abemaciclib. Assignee Mylan Laboratories Limited.WO 2019102492. 2019.
Albrecht, Wolfgang; Rabe, Sebastian. Abemaciclib form IV. Assignee Ratiopharm GmbH. WO 2017108781. 2017.
